文献速递白血病淋巴瘤

大颗粒淋巴细胞白血病的现代观点

A modern view of LGL leukemia.
PubMed 文献 · Blood · 2024-01-01

大颗粒淋巴细胞白血病(LGLL)是T或NK细胞毒性细胞克隆性扩增的罕见慢性淋巴增殖性疾病,常伴自身免疫病。JAK-STAT通路激活及STAT3功能获得性突变在发病中起关键作用,多数患者病程惰性但最终需免疫抑制治疗,靶向治疗正在发展中。

要点

  • LGLL多见于老年患者,中位年龄66.5岁,常伴类风湿关节炎等自身免疫病。
  • JAK-STAT通路激活及STAT3功能获得性突变促进生存、增殖与细胞毒性。
  • 多数患者最终需治疗,免疫抑制剂为主,JAK-STAT抑制剂等靶向治疗正在发展。

核心结论

  • LGLL为惰性但通常不可治愈的慢性淋巴增殖性疾病,多数患者最终需治疗,靶向治疗正在发展中。

研究设计与样本

  • 综述,总结LGLL的分子发病机制、临床特征与治疗进展。

主要发现

  • 慢性T-LGLL和NK-LGLL为惰性病程,患者中位年龄66.5岁,与EBV诱导的侵袭性NK-LGLL不同。
  • LGLL常伴自身免疫病,最常为类风湿关节炎,推测自身/同种抗原参与疾病启动。
  • IL-15、MIP-1和RANTES等促炎细胞因子触发大颗粒淋巴细胞扩增,促炎环境导致增殖与凋亡通路失调。
  • 多数患者存在JAK-STAT通路信号激活,已报道复发性STAT3功能获得性突变,促进生存、增殖与细胞毒性。
  • 近期发现TET2、KMT2D等表观遗传相关复发性突变及CCL22等免疫微环境交互。

临床怎么用

  • 治疗以免疫抑制药物为主,即环磷酰胺、甲氨蝶呤和环孢素。
  • 靶向方法包括JAK-STAT抑制剂、细胞因子靶向治疗及去甲基化药物,为仍不可治愈的疾病开辟新方向。
  • 尽管病程惰性,已发表系列提示多数患者最终需治疗,但许多患者可长期观察而无需治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Large granular lymphocytic leukemia (LGLL) is a rare lymphoproliferative chronic disorder characterized by expansion of either T or natural killer (NK) cytotoxic cells. In contrast to Epstein-Barr virus-induced aggressive NK-LGLL, chronic T-LGLL and NK-LGLL are indolent diseases affecting older patients with a median age of 66.5 years. LGLL is frequently associated with autoimmune disorders, most frequently rheumatoid arthritis. An auto-/alloantigen is tentatively implicated in disease initiation. Large granular lymphocyte expansion is then triggered by proinflammatory cytokines such as interleukin-15, macrophage inflammatory protein 1 (MIP-1), and RANTES (regulated upon activation, normal T cell expressed, and secreted). This proinflammatory environment contributes to deregulation of proliferative and apoptotic pathways. After the initial description of the JAK-STAT pathway signaling activation in the majority of patients, recurrent STAT3 gain-of-function mutations have been reported. The JAK-STAT pathway plays a key role in LGL pathogenesis by promoting survival, proliferation, and cytotoxicity. Several recent advances have been made toward understanding the molecular landscapes of T- and NK-LGLL, identifying multiple recurrent mutations affecting the epigenome, such as TET2 or KMT2D, and cross talk with the immune microenvironment, such as CCL22. Despite an indolent course, published series suggest that the majority of patients eventually need treatment. However, it is noteworthy that many patients may have a long-term observation period without ever requiring therapy. Treatments rely upon immunosuppressive drugs, namely cyclophosphamide, methotrexate, and cyclosporine. Recent advances have led to the development of targeted approaches, including JAK-STAT inhibitors, cytokine targeting, and hypomethylating agents, opening new developments in a still-incurable disease.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Marchand T, Lamy T, Loughran TP, et al. A modern view of LGL leukemia. Blood. 2024. PMID: 38848524. doi:10.1182/blood.2023021790

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。